Oncobiologics allies with inVentiv on biosimilars development

Oncobiologics and the CRO inVentiv Health have joined forces to develop a slate of biosimilars. The Cranbury, NJ-based biotech says they will focus on knockoffs of Humira, Rituxan, Avastin, Herceptin and Erbitux. A variety of new partnerships have been created over the past two years as players position themselves for the arrival of biosimilars, which promise to shave anywhere from 20% to 30% off the cost of some high-profile biologics. At a later point the two partners say their collaboration may be expanded to include novel therapies. FierceCRO article | Release